Blood Podcast How I Treat series on Acute Myeloid Leukemia
Aug 14, 2025
Join Dr. Selina Luger and a panel of AML experts: Dr. Andrew Wei, a researcher on azacitidine and venetoclax at the Peter MacCallum Cancer Centre; Dr. Gail Roboz, who specializes in maintenance therapy at Weill Cornell Medicine; Dr. Eunice Wang, who addresses secondary AML challenges at Roswell Park; and Dr. Courtney DiNardo, focused on targeted therapies at MD Anderson. They discuss groundbreaking outpatient therapies, the complexities of maintenance strategies, and advancements in differentiating agents that may improve patient outcomes.
AI Snips
Chapters
Transcript
Episode notes
Shift To Targeted, Outpatient AML Care
- AML treatment has shifted from one-size-fits-all cytotoxic regimens to many targeted oral therapies over the past 7–8 years.
- This enables outpatient care and expands who treats AML, raising variability in familiarity with new drug toxicities.
Act Fast On Differentiation Syndrome
- Monitor for differentiation syndrome (DS) when using agents that release the differentiation block and start corticosteroids promptly.
- Use dexamethasone 10 mg BID and consider holding the drug, since stopping alone may not work due to long drug half-lives.
DS Timing And Combination Effects
- Differentiation syndrome timing varies by agent, often later than in APL, typically around weeks 3–4 but can recur after rechallenge.
- DS appears less frequent when targeted agents are combined with cytotoxic therapies like azacitidine or 7+3.